Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03775382 · ClinicalTrials.gov registry record · NA
Mechanisms of Impaired Brain Blood Flow With Aging
A NA study, sponsored by University of Delaware.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
NCT03775382 is a NA study that has completed, run by University of Delaware. The registered enrollment target is 34 participants.
The verdict
NCT03775382, a NA study, has completed, sponsored by University of Delaware.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
Study Summary
Aging is the primary risk factor for Alzheimer's disease (AD), which is a rapidly growing public health concern. Understanding the mechanisms of normal brain aging may provide insight into the factors linking advancing age to increased risk for AD and thereby lead to new therapeutic targets for preventing or slowing AD progression. Cardiovascular changes, including impaired cerebrovascular function, occur with aging and may increase risk for AD; however, the mechanisms by which cerebrovascular function becomes impaired in older adults are incompletely understood. The overall goal of this project is to examine potential mechanisms of age-related declines in cerebrovascular function in humans. The investigators hypothesize that brain macro-vascular endothelial dysfunction, secondary to oxidative stress, plays an important role in mediating age-related changes in brain blood flow and cerebrovascular reactivity. The results of this pilot study have the potential to identify novel targets of cerebrovascular aging and will help guide the design of future clinical trials aimed at improving cerebral blood flow in older adults.
Interventions
- OTHER Normal Saline
- OTHER Ascorbic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2017-10-30 |
| Est. Completion | 2022-06-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03775382
The ClinicalTrials.gov registry entry for NCT03775382 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Delaware, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal Saline is the first listed.
NCT03775382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03775382 about?
NCT03775382 is a clinical study titled "Mechanisms of Impaired Brain Blood Flow With Aging". Aging is the primary risk factor for Alzheimer's disease (AD), which is a rapidly growing public health concern. Understanding the mechanisms of normal brain aging may provide insight into the factors linking advancing age to increased risk for AD and thereby lead to new therapeutic targets for prev...
What is the current status of trial NCT03775382?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2017-10-30. Estimated completion is 2022-06-01.
What interventions are being tested in trial NCT03775382?
The interventions under investigation include: Normal Saline (OTHER), Ascorbic Acid (OTHER).
Who is sponsoring clinical trial NCT03775382?
This trial is sponsored by University of Delaware, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.